$LYEL News

Down 27% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround

Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference

Needham Reiterates Buy on Lyell Immunopharma, Maintains $44 Price Target

Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer

Lyell Immunopharma Completes Transfer For LYL273 Candidate To LyFE Manufacture Center In Washington

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

Stifel Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $36

B. Riley Securities Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $44

Wall Street Analysts Think Lyell Immunopharma (LYEL) Could Surge 176.02%: Read This Before Placing a Bet

Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Citizens Reiterates Market Outperform on Lyell Immunopharma, Maintains $34 Price Target

Needham Reiterates Buy on Lyell Immunopharma, Maintains $44 Price Target

Lyell Immunopharma: Undervalued Ahead Of A Major CAR-T Inflection

Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress

Lyell Immunopharma Announces Data From Its Phase 1/2 Clinical Study Of Rondecabtagene Autoleucel In Participants With Relapsed Or Refractory Large B-cell Lymphoma Shows Manufacturing Success Rate Of 97%

Lyell Immunopharma, Inc. (LYEL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Is Lyell Immunopharma (NASDAQ:LYEL) In A Good Position To Deliver On Growth Plans?

HC Wainwright & Co. Reiterates Buy on Lyell Immunopharma, Maintains $45 Price Target

Needham Reiterates Buy on Lyell Immunopharma, Maintains $44 Price Target

Lyell Immunopharma's Cancer Therapy Shows Improved Safety in Phase 1 Study